N/A
Completed N=33
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
Chronic Migraine, Headaches
Source: ClinicalTrials.gov NCT01749410 ↗
Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Sep 2015
Primary outcomePrimary: Change From Baseline in the Number of Headache Days — 19.08; 6.25 Days
Summary
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in the Number of Headache Days |
19.08; 6.25 | — |
Eligibility Criteria
Inclusion Criteria
- 15 or more headache days over a 30 day period
- A minimum of 7 treatment cycles with onabotulinumtoxinA
Exclusion Criteria
- Any treatment cycle dose of onabotulinumtoxinA greater than 200 units
Data sourced from ClinicalTrials.gov (NCT01749410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.